Hepasel

Biphenyl Dimethyl Dicarboxylate

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hepasel

Hepasel is a specific medicinal preparation containing the active substance Biphenyl Dimethyl Dicarboxylate (DDB), primarily classified as a hepatoprotective agent intended to support and protect the liver.

Quick Facts

Property	Description
Active Ingredient	Biphenyl Dimethyl Dicarboxylate (DDB)
Form	Oral tablets or pilules
Pharmacological Class	Hepatoprotective agent
General Purpose	Support and protect liver function
Origin	Synthetic derivative (related to Schisandra chinensis)

What Type of Medicine is Hepasel?

Hepasel is a medicine whose core component, Biphenyl Dimethyl Dicarboxylate, places it within the therapeutic category of hepatoprotective agents (hepatoprotectants). This classification indicates the medicine's fundamental role is to support the health and functional capacity of the liver, an organ essential for the body's metabolism and detoxification. The compound's established function is to provide systemic defense and stabilization for the hepatic system, making it a recognized choice in certain regions for addressing liver challenges.

Composition and Origin: Is Biphenyl Dimethyl Dicarboxylate Synthetic?

The active ingredient is Biphenyl Dimethyl Dicarboxylate, a precise chemical compound that is categorized as a synthetic derivative. This means it is manufactured through controlled chemical processes, differentiating it from crude herbal extracts, although its molecular structure is chemically related to Schizandrin C, a compound found naturally in the traditional herb Schisandra chinensis. The drug is prepared for oral administration, typically available as tablets or pilules, which ensures reliable and measurable delivery of the active substance. The compound is noted for its ability to stabilize liver function markers in clinical settings.

How Does Hepasel Generally Help the Liver?

The primary functional principle of Hepasel is rooted in its role as a potent antioxidant agent within the liver cells. This action involves neutralizing highly reactive molecules called free radicals and significantly limiting lipid peroxidation, a destructive cellular process. This mechanism directly contributes to the maintenance of cell integrity and function, thereby providing a general therapeutic benefit: helping the liver stabilize and restore key biochemical indicators, such as liver enzyme levels, toward a healthy range when under metabolic stress.

What side effects are possible with Hepasel?

Possible Side Effects and Safety Information for Hepasel

Overview of Adverse Reactions

The most significant and documented safety concern associated with Hepasel is the risk of Drug-Induced Liver Injury (DILI). This hepatotoxicity can manifest as elevated liver function tests (LFTs), specifically high levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are signs of liver cell damage. The official classification of adverse events typically follows the ICH/EMA frequency standards, although specific liver-related risks are highlighted based on their clinical severity.

Serious and Clinically Significant Risks

Regulatory agencies have documented the potential for serious adverse reactions, including severe liver injury and, in rare instances, hepatic failure or the need for liver transplantation. These events have prompted specific safety monitoring requirements. Patients with underlying liver conditions, such as pre-existing hepatic impairment or chronic hepatitis, are recognized as a population requiring particular caution due to their potentially increased susceptibility to liver-related risks.

Safety Monitoring and Restrictions

Official regulatory documents emphasize the need for robust risk mitigation measures for patients receiving Hepasel. This includes the mandatory implementation of a monitoring program involving regular measurement of liver enzyme levels throughout the course of treatment. The drug’s regulatory labeling contains restrictions that necessitate the proactive exclusion of other competing causes of liver injury before attributing the event to Hepasel. Caution is advised when administering the drug, and dose adjustments or discontinuation may be required based on the severity of adverse hepatic reactions, as defined in the regulatory texts.

Overdose and Emergency Response

The official regulatory profile for Hepasel (Biphenyl Dimethyl Dicarboxylate) emphasizes the required emergency response protocol for acute intoxication, as specific clinical data on overdose manifestations is not detailed in publicly available government prescribing information.

Documented Overdose Manifestations and Outcomes

No specific clinical signs, symptoms, or laboratory abnormalities resulting from an acute overdose of Biphenyl Dimethyl Dicarboxylate are formally documented in publicly available government regulatory product labeling. Similarly, no specific severe or life-threatening outcomes are formally detailed in official documents.

Official Emergency Actions and When to Seek Help

Seek immediate medical attention should an overdose be suspected, in accordance with regulatory guidance for all prescription medicines. Contact emergency services immediately if the affected individual displays signs of acute intoxication or severe physical distress. Immediate medical help is required for any suspected overdose.

Management Protocol and Monitoring

The management approach is guided by the official regulatory statement that no specific antidote is known for Biphenyl Dimethyl Dicarboxylate intoxication. Therefore, the required protocol is symptomatic and supportive treatment. Post-ingestion management requires that hospital monitoring and continuous observation of vital functions may be necessary.

Therapeutic Uses of Hepasel

What Hepasel treats: Main Uses and Benefits

Hepasel is commonly used as a supportive agent across therapeutic domains involving chronic liver stress. Primary applications include the management of chronic liver diseases and drug-induced hepatic damage.

The medication is generally applied in clinical contexts that require additional symptomatic support. It is relevant in conditions characterized by periods of heightened symptoms, including chronic viral hepatitis (Hepatitis B and C), toxic hepatitis, and drug-induced hepatic injury associated with certain hepatotoxic medical treatments. A key therapeutic use is applied in addressing elevated blood alanine aminotransferase (ALT) levels, which are objective signs of organ-specific functional stress.

This support contributes to supporting liver functional stability and may assist with maintaining functional stability for patients facing long-term physiological stress. This application provides support that helps ease the overall symptom burden.

Quick Fact: Support During Physiological Stress Hepasel is commonly used to provide support in scenarios involving liver damage caused by external factors. It may assist with maintaining functional stability during challenging medical phases, which helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

The eligibility for using Hepasel (Biphenyl Dimethyl Dicarboxylate) is strictly defined by official regulatory guidelines. The medicine is primarily approved for adults seeking supportive care for chronic liver diseases where the condition is stable.

Populations Who Must Not Use Hepasel (Contraindications)

Hepasel is contraindicated and must not be used by individuals with a known hypersensitivity or allergic reaction to the active substance, Biphenyl Dimethyl Dicarboxylate, or to any of the product's inactive components.

Populations with Use Restrictions

Regulatory authorities define specific populations for whom the medicine is not recommended or restricted:

Pediatric Population: Use is not established in children and adolescents (under 18 years of age) due to insufficient safety data.
Pregnancy and Lactation: Use is not recommended during pregnancy or breastfeeding as controlled human safety data are absent.
Disease Severity: The medicine is restricted from use in patients experiencing severe acute hepatitis or severe, uncontrolled liver dysfunction, as it is intended for supportive, rather than acute, therapeutic management.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns and restrictions for Hepasel (Biphenyl Dimethyl Dicarboxylate) as stipulated in government regulatory-aligned documentation.

Formal Restricted Co-Administration

Regulatory documentation establishes formal restrictions against combining Hepasel with several specific active substances. These restrictions were derived from mandatory exclusion criteria in regulatory-aligned clinical studies.

Classification	Restricted Substances
Prohibited Combinations	Levodopa, Altretamine, Cisplatin, and Statins (a class of lipid-regulating agents)

Documented Combination Patterns and Restrictions

Certain combinations have been formally documented or are subject to population-specific constraints as outlined in official records:

Documented Co-Administration: The combination of Hepasel with Ursodeoxycholic Acid and Garlic Oil has been noted and investigated in clinical trial settings, documenting the co-administration pattern.
Substance Restriction: Use is formally restricted in patients with a history of alcohol abuse.
Population Restriction: Official restrictions formally exclude the co-administration of Hepasel in patients with co-infection of HIV, Hepatitis B (HBV), or Hepatitis C (HCV). These constraints are based on predefined requirements within regulatory-aligned studies.

There is no explicit, officially documented information detailing pharmacokinetic interaction mechanisms, such as CYP enzyme or transporter effects, nor are there regulatory statements mandating a specific time-based separation of doses.

Mechanism of Action

How Hepasel Works: Pharmacodynamic Mechanism

Hepasel's mechanism of action is focused on cellular stability and the modulation of endogenous defense pathways localized within the liver's hepatocytes. The active substance, Biphenyl Dimethyl Dicarboxylate (DDB), operates through two complementary domains to influence enzyme activity and structural integrity.

Modulation of Antioxidant Enzyme Activity

DDB acts as an inducer and enhancer of key intracellular antioxidant enzymes, specifically Glutathione Peroxidase (GSH-Px) and Superoxide Dismutase (SOD). This interaction elevates the cell's capacity to neutralize Reactive Oxygen Species (ROS) (free radicals), contributing to an increase in internal antioxidant capacity.

Direct Inhibition of Lipid Peroxidation

Complementary to enzyme modulation, DDB directly scavenges free radicals, thereby interrupting the destructive chemical chain reaction known as lipid peroxidation within cell membranes. The ultimate physiological effect of halting this process is the stabilization of the hepatocyte membrane integrity. This structural maintenance limits the uncontrolled leakage of intracellular enzymes, such as transaminases, into the bloodstream, influencing the stability of hepatic biochemical parameters.

Dosage and Administration Information

How to Use Hepasel

The administration of Hepasel, which contains the active substance Biphenyl Dimethyl Dicarboxylate (DDB), is governed by specific official prescribing instructions to ensure standardized use. The medicine is classified as a hepatoprotective agent and is consistently used through the oral route as a tablet or pilule.

Standard Dosing and Frequency

The official dosage schedule for adults is defined by both the individual dose amount and the frequency of administration throughout the day. The drug is typically used as part of a long-term, supportive regimen for chronic conditions.

Parameter	Official Instruction
Route of Administration	Oral (by mouth)
Dose per Administration	One to two tablets (25 mg to 50 mg)
Dosing Frequency	Three times daily (TID)
Preparation	None; tablets must be swallowed whole

The Standardized Dosing Regimen mandates that the tablet be taken multiple times per day to achieve the necessary total daily intake, which falls within the range of 75 mg to 150 mg of DDB.

Administration Context

Hepasel is generally intended to be administered independent of food intake, as no universal relationship with meals is specified in the primary official summaries. Dosing instructions primarily cover adults, and the use is for an extended supportive course rather than a short, acute cycle. If a dose is missed, official guidance advises taking it as soon as it is remembered unless it is almost time for the next scheduled dose, thereby avoiding the administration of a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hepasel

Evidence Overview for Chronic Viral Hepatitis

Research examining Hepasel (Biphenyl Dimethyl Dicarboxylate) was studied for adults with chronic viral hepatitis, particularly Hepatitis B and C. Studies evaluated the medicine, often in Randomized Controlled Trials (RCTs), for use alongside standard antiviral treatments. These studies were designed to examine changes in key outcomes related to physiological strain or stress, namely the liver enzyme levels Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST).

Findings describe patterns observed in these studies, including measurements of ALT levels showed patterns of change during the study period. This research highlights changes measured when the medicine was evaluated in patients with persistently elevated enzymes over short-term follow-up durations, typically a few weeks to six months. However, long-term effects are not fully established. Evidence is limited regarding the medicine's effect on major clinical outcomes beyond temporary enzyme shifts.

Research Findings for Toxic Liver Stress

Hepasel was studied for situations involving toxic hepatitis and drug-induced liver injury. The evidence base includes controlled clinical reports and pre-clinical research. Researchers examined changes in ALT/AST levels following exposure to toxic agents. Studies reported patterns where the elevation of these key liver enzymes appeared to shift during the period the medicine was evaluated in. These findings are primarily short-term and focus on the immediate biochemical response. The certainty remains low because many findings come from animal models, and the extrapolation challenges from pre-clinical results to human clinical outcomes remain a limitation.

Evidence Gaps and Research Uncertainties

A core uncertainty lies in the distinction between biochemical changes (enzyme shifts) and histological outcomes (tissue improvement). Research has not consistently shown that the temporary changes observed in enzyme levels correlate with definitive, long-term improvement in liver tissue health (fibrosis or scarring). Additionally, findings regarding the medicine’s impact on viral activity in chronic viral hepatitis were mixed and inconsistent. Finally, subgroup findings are uncertain, as many results apply only to the populations studied, and data for special populations remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Hepasel (FAQ)

Q: What should I do if I miss a dose of Hepasel?

If a dose is missed, official prescribing instructions recommend taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, it is recommended that the missed dose be skipped. Regulatory guidance cautions against administering a double dose to make up for one that was missed.

Q: Is it okay to take Hepasel with food?

According to the official product information, Hepasel is generally intended to be administered independent of food intake. Regulatory summaries do not specify a universal relationship with meals. This indicates the medicine is taken independent of food intake, and no universal relationship with meals is specified in the regulatory summaries.

Q: Can children take Hepasel?

Official regulatory labeling indicates that the use of Hepasel is not established for the pediatric population, which includes children and adolescents under 18 years of age. This restriction is in place due to the lack of sufficient safety data for this patient population.

Q: Can I use Hepasel if I am pregnant or breastfeeding?

The official regulatory labeling states that use is not recommended during pregnancy or while breastfeeding. Regulatory documents state this restriction applies because controlled human safety data concerning the drug's use during these periods is absent.

Q: What are the most common side effects of Hepasel?

Official documentation following regulatory standards reports that common adverse events typically include gastrointestinal disturbances (such as nausea or stomach upset). It is also noted that Drug-Induced Liver Injury (DILI) is a clinically significant risk that is documented and requires ongoing monitoring during treatment.

Q: How should I dispose of expired Hepasel?

Unused or expired Hepasel must be disposed of in compliance with local, regional, and national regulations. Regulatory instructions state that the medicine should be delivered to an approved waste disposal plant and must not be flushed into surface water or sanitary sewer systems to avoid environmental release.

How should Hepasel be stored and disposed of?

Storage Requirements

Hepasel (Biphenyl Dimethyl Dicarboxylate) must be stored under specific environmental constraints as defined by regulatory documents to preserve its stability.

Condition Type	Requirement
Temperature	Do not store above 30°C in a cool, well-ventilated area.
Protection	Keep the medicine in its original container, tightly closed, to protect it from moisture and light.
Child Safety	The product must be stored locked up and kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Hepasel must be disposed of in compliance with local, regional, and national regulations. The product and its container must be delivered to an approved waste disposal plant. Disposal instructions explicitly state that the medicine should not be flushed into surface water or sanitary sewer systems to avoid environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Myanmar

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z